Laurent Cipriani / Pool / APThis June 16, 2020, file photo shows the vaccine unit at the Sanofi Pasteur plant in central France. (Laurent Cipriani / Pool / AP)
Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of its experimental COVID-19 vaccine to the United States.
The United States will pay up to $2.1 billion “for development including clinical trials, manufacturing, scale-up and delivery of its vaccine,” the companies said in a statement. Sanofi will get the bulk of the funds.
The U.S. government has a further option for the supply of an additional 500 million doses as part of its Operation Warp Speed program.
“The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” U.S. Health and Human Services Secretary